Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868628 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2 study of Multiple System Atrophy, sponsored by Tiziana Life Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06868628: Recruiting Phase 2 study of Multiple System Atrophy, sponsored by Tiziana Life Sciences.
NCT06868628 is a Phase 2 study of Multiple System Atrophy that is actively recruiting participants, run by Tiziana Life Sciences. The registered enrollment target is 5 participants, below the 268-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868628, a Phase 2 study of Multiple System Atrophy, is actively recruiting participants, sponsored by Tiziana Life Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
Conditions Studied
Interventions
- DRUG Foralumab Nasal
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 2 |
What NCT06868628 shows while recruiting
NCT06868628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 268-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Foralumab Nasal is the first listed.
NCT06868628 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06868628 about?
NCT06868628 is a clinical study titled "A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)". A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
What is the current status of trial NCT06868628?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2025-05-19. Estimated completion is 2027-04-01.
What conditions does trial NCT06868628 study?
This clinical trial studies the following conditions: Multiple System Atrophy.
What interventions are being tested in trial NCT06868628?
The interventions under investigation include: Foralumab Nasal (DRUG).
Who is sponsoring clinical trial NCT06868628?
This trial is sponsored by Tiziana Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868628 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06868628's enrollment target sits among peer trials
5 30th of 30 higher than 1 of 30 other Multiple System Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple System Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
RECRUITING · Phase 2
-
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
RECRUITING · Phase 2
-
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
RECRUITING · Phase 2
-
A Study of Lu AF82422 in Participants With Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI